glp-1 in obesity Glucagon-like peptide 1 the pathophysiology and pharmacotherapy of clinical Weighing the risk of GLP-1

Liang, Y., Zhou, R., Fu, X., Wang, C

Chhaya Makhija, MD, DipABLM Board-Certified Endocrinologist | Lifestyle Medicine Physician | Founder, Unified Endocrine & Diabetes Care Lafayette Fresno California Telemedicine (including Silicon Valley, Palo Alto, Menlo Park, San Francisco, Walnut Creek, Oakland, Sacramento) Watch or Listen to the Full Episode For a deeper dive into the science and real-world clinical nuance:

Liraglutide differs from semaglutide in several ways, but storage requirements are broadly similar

Jaisinghani says that clinicians have learned from their experience prescribing Rybelsus, a GLP-1 pill that was approved for treating diabetes in 2019, that medication adherence can depend a lot on the patients preferences